Rani Therapeutics Appoints Michelle Gilson to Board, Audit Chair

What Happened

• Rani Therapeutics Holdings, Inc. announced that Michelle Gilson was appointed to the Company’s Board of Directors effective August 1, 2026, and was named chair of the Audit Committee. Her term runs until the earlier of the next annual meeting, her successor’s qualification, or her death, resignation, or removal.
• Ms. Gilson, age 34, served as Chief Financial Officer of Arcellx, Inc. from May 2022 until its acquisition by Gilead Sciences in April 2026. Her prior roles include Senior Biotechnology Equity Research Analyst and Managing Director at Canaccord Genuity (2018–2022) and positions at Jefferies, Nomura, Oppenheimer and Goldman Sachs. She holds a B.S. in Business Administration from USC.

Key Details

• Appointment effective: August 1, 2026.
• Committee role: Chair of the Audit Committee.
• Recent experience: CFO of Arcellx (May 2022 – Apr 2026 acquisition by Gilead).
• Compensation and protections: Ms. Gilson will be compensated under the Company’s Non‑Employee Director Compensation Policy (referenced in the 10‑Q filed May 15, 2026) and will enter the Company’s standard indemnification agreement (form referenced in the Company’s S‑1).

Why It Matters

• Governance impact: Adding an experienced biotech finance executive as Audit Committee chair strengthens financial oversight and board expertise on accounting, reporting and capital markets matters—areas important to investors monitoring financial controls and disclosure.
• No related‑party issues disclosed: The filing states there are no arrangements or understandings with Ms. Gilson, no family relationships with existing directors or officers, and no reportable related‑party transactions per Item 404.
• Practical effect: This is a corporate governance update rather than an operational or financial results disclosure; investors should view it as a board-level change that may influence oversight and investor confidence but not an immediate business or revenue event.